Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

67.23 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Sep 2, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	61
Open	67.23
Bid (Size)	67.00 (100)
Ask (Size)	68.00 (100)
Prev. Close	67.23
Today's Range	67.23 - 67.23
52wk Range	17.27 - 67.85
Shares Outstanding	60,717,176
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Travere Therapeutics Sees FILSPARI FSGS Launch Top Expectations, Expands Renal Pipeline ↗

August 18, 2026

Travere Therapeutics (NASDAQ:TVTX) is pursuing growth through expanded use of FILSPARI in rare kidney diseases while advancing a late-stage treatment candidate for classical homocystinuria and building...

Via MarketBeat

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 12, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Performance

YTD	+70.1%	+70.1%
1 Month	+22.3%	+22.3%
3 Month	+48.7%	+48.7%
6 Month	+138.6%	+138.6%
1 Year	+270.4%	+270.4%

More News

Travere Therapeutics (TVTX) Q2 2026 Earnings Call Transcript ↗

August 11, 2026

Via The Motley Fool

Travere Therapeutics (NASDAQ:TVTX) Beats Q2 Revenue Estimates on FILSPARI Sales Growth ↗

August 04, 2026

Via Chartmill

Travere Therapeutics (NASDAQ:TVTX) Earns Perfect Ratings in Breakout Setup Screen ↗

July 28, 2026

Via Chartmill

Travere Therapeutics (NASDAQ:TVTX): High Growth Momentum Stock with Breakout Setup ↗

July 25, 2026

Via Chartmill

Travere Therapeutics (NASDAQ:TVTX) - High Growth Momentum and Technical Breakout Setup ↗

July 02, 2026

Via Chartmill

Travere Therapeutics to Participate at Upcoming Investor Conferences

August 05, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Travere Therapeutics Q2 Earnings Call Highlights ↗

August 04, 2026

Via MarketBeat

Travere Therapeutics Reports Second Quarter 2026 Financial Results

August 04, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Travere Therapeutics to Report Second Quarter 2026 Financial Results

July 28, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 10, 2026

From Travere Therapeutics, Inc.

Via Business Wire

QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now ↗

June 19, 2026

Via InvestorPlace

Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027

June 16, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 11, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress

June 04, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases

June 02, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy

May 27, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 12, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Validating headline phrasing and editorial resonance A Director Cashes In Near the Top, but What Remains Matters ↗

May 10, 2026

Via The Motley Fool

Travere Therapeutics to Participate at Upcoming Investor Conferences

May 07, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes

May 06, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes

May 05, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Travere Therapeutics Analysts Increase Their Forecasts Following Q1 Earnings ↗

May 05, 2026

Via Benzinga

Travere (TVTX) Q1 2026 Earnings Transcript ↗

May 04, 2026

Via The Motley Fool

Frequently Asked Questions

Is Travere Therapeutics, Inc. - Common Stock publicly traded?

Yes, Travere Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Travere Therapeutics, Inc. - Common Stock trade on?

Travere Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Travere Therapeutics, Inc. - Common Stock?

The ticker symbol for Travere Therapeutics, Inc. - Common Stock is TVTX on the Nasdaq Stock Market

What is the current price of Travere Therapeutics, Inc. - Common Stock?

The current price of Travere Therapeutics, Inc. - Common Stock is 67.23

When was Travere Therapeutics, Inc. - Common Stock last traded?

The last trade of Travere Therapeutics, Inc. - Common Stock was at 09/02/26 04:00 PM ET

What is the market capitalization of Travere Therapeutics, Inc. - Common Stock?

The market capitalization of Travere Therapeutics, Inc. - Common Stock is 4.08B

How many shares of Travere Therapeutics, Inc. - Common Stock are outstanding?

Travere Therapeutics, Inc. - Common Stock has 4B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.